Pacer Advisors Inc. Invests $219,000 in Krystal Biotech, Inc. (NASDAQ:KRYS)

Pacer Advisors Inc. bought a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,400 shares of the company’s stock, valued at approximately $219,000.

A number of other institutional investors have also added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB acquired a new stake in Krystal Biotech in the third quarter valued at $40,000. Values First Advisors Inc. acquired a new stake in Krystal Biotech in the 3rd quarter valued at about $53,000. GAMMA Investing LLC increased its position in Krystal Biotech by 184.8% during the third quarter. GAMMA Investing LLC now owns 430 shares of the company’s stock worth $78,000 after buying an additional 279 shares during the last quarter. Huntington National Bank raised its stake in Krystal Biotech by 97.6% in the third quarter. Huntington National Bank now owns 573 shares of the company’s stock valued at $104,000 after buying an additional 283 shares during the period. Finally, Blue Trust Inc. lifted its position in shares of Krystal Biotech by 242.4% in the third quarter. Blue Trust Inc. now owns 582 shares of the company’s stock valued at $107,000 after buying an additional 412 shares during the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the sale, the insider now owns 1,475,882 shares in the company, valued at approximately $243,195,835.96. This trade represents a 1.67 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 14.10% of the stock is owned by company insiders.

Krystal Biotech Trading Up 1.4 %

Shares of KRYS opened at $161.30 on Wednesday. Krystal Biotech, Inc. has a 12 month low of $107.50 and a 12 month high of $219.34. The firm’s 50 day moving average is $164.94 and its 200-day moving average is $178.99. The stock has a market capitalization of $4.64 billion, a PE ratio of 91.13 and a beta of 0.84.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.07. The firm had revenue of $83.84 million during the quarter, compared to analysts’ expectations of $82.94 million. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The company’s quarterly revenue was up 879.9% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.67) EPS. Equities research analysts predict that Krystal Biotech, Inc. will post 3.22 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $221.00 price objective on shares of Krystal Biotech in a research report on Wednesday, December 18th. Chardan Capital reiterated a “buy” rating and issued a $212.00 price target on shares of Krystal Biotech in a research note on Wednesday, December 18th. Finally, Citigroup raised their price objective on shares of Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Krystal Biotech has an average rating of “Buy” and an average price target of $206.67.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).